Results 71 to 80 of about 4,421 (195)

Exercise or Fasting in Individuals With Type 2 Diabetes Receiving Once‐Weekly Basal Insulin Icodec

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8523-8532, September 2026.
ABSTRACT Aims To investigate glucose levels and hypoglycaemia risk during exercise or fasting in adults with type 2 diabetes (T2D) treated with once‐weekly basal insulin icodec. Materials and Methods Thirty basal insulin‐treated, physically active individuals with T2D (18–75 years, glycated haemoglobin ≤ 75 mmol/mol, peak oxygen uptake > 20 mL/kg/min ...
Thomas R. Pieber, Harpreet S. Bajaj, Gabriele Fluhr, Klara R. Klein, Thaís M. Pagliaro Rocha, Harald Sourij, Eva Svehlikova, Keerthana Udupa, Sara K. Watt, Maria Willerslev‐Olsen, Rasmus Ribel‐Madsen   +10 more
wiley   +1 more source

Improved health status with insulin degludec compared with insulin glargine in people with Type 1 diabetes

, 2012
Aims: The efficacy and safety of insulin degludec (degludec), a new-generation ultra-long-acting basal insulin, was compared with insulin glargine (glargine) in people with Type 1 diabetes mellitus in a 16-week, open-label, randomized trial.
K. I. Birkeland, P. D. Home, Meneghini, L.,, L. Meneghini, Birkeland, K. I.,, U. Wendisch, J. Jendle, Home, P. D.,, T. Johansen, Johansen, T.,, T. E. Christensen, A. P. Roberts, Wendisch, U.,, Roberts, A. P.,, Ratner, R. E.,, Christensen, T. E.,, Jendle, Johan,, R. E. Ratner   +17 more
core   +1 more source

Degludec hospital trial: A randomized controlled trial comparing insulin degludec U100 and glargine U100 for the inpatient management of patients with type 2 diabetes.

, 2021
AIMS: Limited data exist about the use of insulin degludec in the hospital. This multicentre, non-inferiority, open-label, prospective randomized trial compared the safety and efficacy of insulin degludec-U100 and glargine-U100 for the management of ...
Tuttle, Katherine, Galindo, Rodolfo J, Migdal, Alexandra L, Urrutia, Maria A, Alicic, Radica, Peng, Limin, Umpierrez, Guillermo E, Lam, David W, Cardona, Saumeth, Perez-Guzman, Citlalli, Zamudio-Coronado, Karla Walkiria, Pasquel, Francisco J, Vellanki, Priyathama, Davis, Georgia M, Fayfman, Maya   +14 more
core  

DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal–Bolus Regimens for Type 2 Diabetes in the UK [PDF]

, 2018
Introduction: The aim of this study was to evaluate the short-term cost-utility of insulin degludec (degludec) versus insulin glargine 100 units/mL (glargine U100) for the treatment of type 2 diabetes in the basal–bolus subgroup of the head-to-head ...
Hallén, N., Valentine, W.J., Hansen, L.L., Buse, J.B., Marso, S.P., Tutkunkardas, D., Pollock, R.F., Gundgaard, J., DEVOTE Study Group   +8 more
core   +1 more source

THE USE OF ULTRA-LONG-ACTING INSULIN ANALOGUE DEGLUDEC IN TYPE 1 DIABETES MELLITUS IN CLINICAL PRACTICE: THE INFLUENCE ON QUALITY OF LIFE AND SATISFACTION WITH TREATMENT

Alʹmanah Kliničeskoj Mediciny, 2016
Background: Maintenance of stable glycemic control is an important prerequisite of effective treatment of patients with type 1 diabetes mellitus (DM).
M. F. Kalashnikova, D. R. Yazykova, N. V. Likhodey, A. V. Zilov, Yu. P. Sych, E. S. Maloletkina, V. V. Fadeev   +6 more
doaj   +1 more source

Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes

, 2015
Philippe Thuillier,1 Zarrin Alavi,2 Véronique Kerlan1 1Department of Endocrinology, Diabetology and Metabolic Diseases, 2French Institute of Health and Medical Research CIC 1412, Medical University Hospital of Brest La Cavale Blanche, Brest ...
Kerlan V, Thuillier P, Alavi Z
core  

Ligand-Controlled Assembly of Hexamers, Dihexamers, and Linear Multihexamer Structures by the Engineered Acylated Insulin Degludec

, 2016
Insulin degludec, an engineered acylated insulin, was recently reported to form a soluble depot after subcutaneous injection with a subsequent slow release of insulin and an ultralong glucose-lowering effect in excess of 40 h in humans.
Svend Havelund (2002834), Gerd Schluckebier (75560), Dorte B. Steensgaard (2002831), Mathias Norrman (75559), Jens K. Thomsen (1871737), Anders V. Friderichsen (2002828), Holger M. Strauss (183808), Ib Jonassen (2002837)   +7 more
core   +1 more source

Data on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice

Сахарный диабет, 2015
Aim: The aim of this study was to evaluate the efficacy and safety of the new ultra-long-acting insulin degludec (Tresiba®) in the treatment of type 2 diabetes in routine clinical practice.Methods: This primary health care clinical observational study ...
Lyudmila Alexandrovna Suplotova, Nikolay Valer'evich Plotnikov, Natal'ya Valer'yanovna Romanova, Larisa Nikolaevna Bel’chikova, Ekaterina Viktorovna Khieva, Marina Vladimirovna Shestakova   +5 more
doaj   +1 more source

Hypoglycemia in Type 2 Diabetes Patients Substituted with Insulin Degludec Aspart from Premixed Insulin Therapy: a Quasi Experimental Study

Pakistan Armed Forces Medical Journal
Objective: To determine whether Insulin Degludec Aspart is associated with a reduced risk of hypoglycemia as compared to premixed Insulin aspart therapy in type-2 diabetes mellitus patients. Study Design: Quasi-experimental study Place and Duration
Komal Mumtaz Malik, Sadia Zafar, Shabana Ali, Mudassir Noor, Noaman Ishaq   +4 more
doaj   +1 more source

Ligand-Controlled Assembly of Hexamers, Dihexamers, and Linear Multihexamer Structures by the Engineered Acylated Insulin Degludec

, 2012
Insulin degludec, an engineered acylated insulin, was recently reported to form a soluble depot after subcutaneous injection with a subsequent slow release of insulin and an ultralong glucose-lowering effect in excess of 40 h in humans.
Friderichsen, A. V., Schluckebier, G., Gerd Schluckebier, Ib Jonassen, Jens K. Thomsen, Havelund, S., Mathias Norrman, Steensgaard, D. B., Jonassen, I., Thomsen, J. K., Anders V. Friderichsen, Svend Havelund, Strauss, H. M., Norrman, M., Dorte B. Steensgaard, Holger M. Strauss   +15 more
core   +1 more source